0001209191-23-044071.txt : 20230801
0001209191-23-044071.hdr.sgml : 20230801
20230801192727
ACCESSION NUMBER: 0001209191-23-044071
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230729
FILED AS OF DATE: 20230801
DATE AS OF CHANGE: 20230801
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: King Andrew James
CENTRAL INDEX KEY: 0001823187
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37345
FILM NUMBER: 231133241
MAIL ADDRESS:
STREET 1: C/O CHINOOK THERAPEUTICS U.S., INC.
STREET 2: 1600 FAIRVIEW AVE. E.
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CHINOOK THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001435049
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 206-485-7051
MAIL ADDRESS:
STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900
CITY: SEATTLE
STATE: WA
ZIP: 98109
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH, INC.
DATE OF NAME CHANGE: 20111107
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH
DATE OF NAME CHANGE: 20080514
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-07-29
0
0001435049
CHINOOK THERAPEUTICS, INC.
KDNY
0001823187
King Andrew James
C/O CHINOOK THERAPEUTICS, INC.
400 FAIRVIEW AVE. NO., 9TH FLOOR
SEATTLE
WA
98109
0
1
0
0
Chief Scientific Officer
0
Common Stock
2023-07-29
4
M
0
3333
A
20325
D
Common Stock
2023-08-01
4
S
0
1168
39.029
D
19157
D
Restricted Stock Units
2023-07-29
4
M
0
3333
0.00
D
2025-07-29
Common Stock
3333
6667
D
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Each RSU represents a contingent right to receive one share of Issuer's common stock.
The RSUs vest as to one-third (1/3) of the total award on the first, second, and third anniversaries of the grant date, subject to the reporting person's continued service to the Issuer on each vesting date.
/s/ Kirk Schumacher, Attorney-in-Fact
2023-08-01